Skip to main content
Erschienen in: Digestive Diseases and Sciences 4/2012

01.04.2012 | Original Article

Patients with Inflammatory Bowel Disease Have a Lower Response Rate to HBV Vaccination Compared to Controls

verfasst von: Mustafa Erhan Altunöz, Ebubekir Şenateş, Atakan Yeşil, Turan Çalhan, Ayşe Oya Kurdaş Övünç

Erschienen in: Digestive Diseases and Sciences | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Hepatitis B (HBV) is a vaccine-preventable infection that may cause severe infections, particularly in patients who are being treated with immunosuppressive therapy [(i.e., inflammatory bowel disease (IBD)]. Limited data are available about IBD patients’ response rate to HBV vaccine.

Aim

To assess the efficacy of HBV vaccine in IBD patients and healthy controls.

Methods

Serological markers of HBV were assessed in IBD patients, and HBV vaccine was administered to seronegative patients. The subsequent determination of anti-HBs antibody was recorded. An adequate immune response (AIR) and an effective immune response (EIR) to HBV were defined as more than 10 and 100 mIU/ml, respectively. The single dose vaccine was administered at 0, 1 and 6 months.

Results

A total of 102 patients with IBD (39 Crohn’s disease, 63 ulcerative colitis; 54 female, 48 male) and 52 (25 female, 27 male) healthy controls were included. Mean age for patients and controls were 38 ± 12 and 31 ± 8, respectively (P < 0.001). Both AIR and EIR were significantly lower in patients than in controls (P < 0.001), but they were similar between patients with CD and UC (P = 0.302). Forty-four (43%) patients were on immunosuppressive therapy before vaccination. After vaccination, 76 and 53% of the patients had AIRs and EIRs, respectively, whereas 100 and 87% of the controls had AIRs and EIRs, respectively (P < 0.001 and P < 0.001, respectively).

Conclusions

The response rate of IBD patients receiving HBV vaccinations were significantly lower compared to controls. The response rate of those receiving immunosuppressive therapy and with active disease was much too low. Vaccination should be given during remission and at immunosuppression-free times.
Literatur
1.
Zurück zum Zitat Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005;307:1920–1925.PubMedCrossRef Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005;307:1920–1925.PubMedCrossRef
2.
Zurück zum Zitat Lu Y, Jacobson D, Bousvaros A, et al. İmmunizations in patients with İnflammatory bowel disease. İnflamm Bowel Dis. 2009;15:1417–1423. Lu Y, Jacobson D, Bousvaros A, et al. İmmunizations in patients with İnflammatory bowel disease. İnflamm Bowel Dis. 2009;15:1417–1423.
3.
Zurück zum Zitat Yeung JH, Goodman KJ, Fedorak RN. Inadequate knowledge of immunization guidelines: A missed opportunity for preventing infection in immunocompromised IBD patients. Inflamm Bowel Dis. 02/18/2011. (Epub ahead of print). doi:10.1002/ibd.21668. Yeung JH, Goodman KJ, Fedorak RN. Inadequate knowledge of immunization guidelines: A missed opportunity for preventing infection in immunocompromised IBD patients. Inflamm Bowel Dis. 02/18/2011. (Epub ahead of print). doi:10.​1002/​ibd.​21668.
4.
Zurück zum Zitat Michel M, Duvoux C, Hezode C, et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still’s disease. J Rheumatol. 2003;30:1624–1625.PubMed Michel M, Duvoux C, Hezode C, et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still’s disease. J Rheumatol. 2003;30:1624–1625.PubMed
5.
Zurück zum Zitat Bernal I, Domenech E, Garcia-Planella E, et al. Opportunistic infections in patients with inflammatory bowel disease undergoing immunosuppressive therapy. Gastroenterol Hepatol. 2003;26:19–22.PubMedCrossRef Bernal I, Domenech E, Garcia-Planella E, et al. Opportunistic infections in patients with inflammatory bowel disease undergoing immunosuppressive therapy. Gastroenterol Hepatol. 2003;26:19–22.PubMedCrossRef
6.
Zurück zum Zitat Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101:1834–1840.PubMedCrossRef Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101:1834–1840.PubMedCrossRef
7.
Zurück zum Zitat WHO Publication. Hepatitis B vaccines: WHO position paper—recommendations. Vaccine. 2009;28:589–590. WHO Publication. Hepatitis B vaccines: WHO position paper—recommendations. Vaccine. 2009;28:589–590.
8.
Zurück zum Zitat Coates T, Wilson R, Patrick G, Andre F, Watson V. Hepatitis B vaccines: Assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther. 2001;23:392–403.PubMedCrossRef Coates T, Wilson R, Patrick G, Andre F, Watson V. Hepatitis B vaccines: Assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther. 2001;23:392–403.PubMedCrossRef
9.
Zurück zum Zitat Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: İmmunization of adults. MMWR Recomm Rep. 2006;55:1–33.PubMed Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: İmmunization of adults. MMWR Recomm Rep. 2006;55:1–33.PubMed
10.
Zurück zum Zitat Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:677–692.PubMedCrossRef Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:677–692.PubMedCrossRef
11.
Zurück zum Zitat Chaparro M, Villagrasa JR, Rodrı′guez NA, Gisbert JP. Immune response to hepatitis B vaccination in patients with inflammatory bowel disease. Gastroenterology. 2010;S138:S197. Chaparro M, Villagrasa JR, Rodrı′guez NA, Gisbert JP. Immune response to hepatitis B vaccination in patients with inflammatory bowel disease. Gastroenterology. 2010;S138:S197.
12.
Zurück zum Zitat Vida Perez L, Gomez Camacho F, Garcia Sanchez V, et al. Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease. Med Clin (Barc). 2009;132:331–335 (Abstract only). Vida Perez L, Gomez Camacho F, Garcia Sanchez V, et al. Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease. Med Clin (Barc). 2009;132:331–335 (Abstract only).
13.
Zurück zum Zitat Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.PubMedCrossRef Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.PubMedCrossRef
14.
Zurück zum Zitat Best WR, Becktel JM, Singleton JW et al. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–444. Best WR, Becktel JM, Singleton JW et al. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–444.
15.
Zurück zum Zitat Gilbert MS, James RS. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. J Adoles Health. 1995;16:12–17. Gilbert MS, James RS. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. J Adoles Health. 1995;16:12–17.
16.
Zurück zum Zitat Tamer A, Karabay O, Koç Nİ. The efficiency of two doses hepatitis B vaccination in health care workers for immunoprophylaxis. Turkiye Klinikleri J Med Sci. 2006;26:24–28. Tamer A, Karabay O, Koç Nİ. The efficiency of two doses hepatitis B vaccination in health care workers for immunoprophylaxis. Turkiye Klinikleri J Med Sci. 2006;26:24–28.
17.
Zurück zum Zitat Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med. 1997;336:296–304.CrossRef Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med. 1997;336:296–304.CrossRef
Metadaten
Titel
Patients with Inflammatory Bowel Disease Have a Lower Response Rate to HBV Vaccination Compared to Controls
verfasst von
Mustafa Erhan Altunöz
Ebubekir Şenateş
Atakan Yeşil
Turan Çalhan
Ayşe Oya Kurdaş Övünç
Publikationsdatum
01.04.2012
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 4/2012
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-011-1980-8

Weitere Artikel der Ausgabe 4/2012

Digestive Diseases and Sciences 4/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.